International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Despite decades of relevant basic and clinical research, active debate continues about the appropriate extent and duration of benzodiazepine use in the treatment of anxiety and related disorders. The primary basis of the controversy seems to be concern among clinicians, regulators, and the public about the dependence potential and the abuse liability of benzodiazepines. This article reports systematically elicited judgments on these issues by a representative panel of 73 internationally recognized experts in the pharmacotherapy of anxiety and depressive disorders, a panel which was constituted by a multistage process of peer nomination. The criterion for inclusion at each stage was the nomination by at least two peers as one of the "professionally most respected physicians of the world with extensive experience and knowledge in the pharmacotherapy of anxiety and depressive disorders." Sixty-six respondents (90%) completed a comprehensive questionnaire covering a wide range of topics relevant to the therapeutic use of benzodiazepines and other medications that might be used for the same purposes. Overall, the expert panel judged that benzodiazepines pose a higher risk of dependence and abuse than most potential substitutes but a lower risk than older sedatives and recognized drugs of abuse. There was little consensus about the relative risk of dependence and abuse among the benzodiazepines. Differences between benzodiazepines with shorter and longer half-lives in inducing withdrawal symptoms are much less clear during tapered than during abrupt discontinuation. There was little agreement about the most important factors contributing to withdrawal symptoms and failure to discontinue benzodiazepines. The pharmacologic properties of the medication may be the most important contributors to withdrawal symptoms. In contrast, the clinical characteristics of the patient may be the most important contributors to failure to discontinue medication. The experts' judgment seems to support the widespread use of benzodiazepines for the treatment of bona fide anxiety disorders, even over long periods. The experts generally viewed dependence and abuse liability as clinical issues amenable to appropriate management, as for other adverse events related to therapy. However, more definitive clinical research on the remaining controversial issues is urgently needed to promote optimal patient care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Numerous reports have identified certain predictors of the occurrence or increased severity of withdrawal symptoms: higher BZD dose (200-204), longer duration of BZD use (202, 203, 205, 206), immediate cessation or rapid tapering of the BZD dose (200, 203, 204, 207-209), history of drug abuse (202, 203), dependence on other drugs (209), personality pathology (e.g.neuroticism and dependency) (203)”
From Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics (2008) · cites this paper as [202]
Citations
Cites
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Use of benzodiazepines in anxiety disorders
Wood, A. J. J., Shader, R. I., & Greenblatt, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281907 · Cited by 341
Abuse liability of benzodiazepines.
Woods, J. H., Katz, J. L., & Winger, G. (1987) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06658-x · Cited by 315
Woods, J. H., & Winger, G. (1995) · Psychopharmacology · doi:10.1007/bf02245824 · Cited by 196
Michelini, S., Cassano, G., Frare, F., & Perugi, G. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-979558 · Cited by 135
Use and abuse of benzodiazepines. Issues relevant to prescribing
Woods, J. H., Katz, J. L., & Winger, G. (1988) · JAMA · doi:10.1001/jama.260.23.3476 · Cited by 99
Pain Management and Chemical Dependency: Evolving Perspectives
Portenoy, R. K. (1997) · JAMA · doi:10.1001/jama.1997.03550070084043 · Cited by 72
Opioid Therapy for Chronic Nonmalignant Pain: Clinicians' Perspective
Portenoy, R. K. (1996) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.1996.tb01871.x · Cited by 67
UHLENHUTH, E. H., Balter, M. B., Ban, T. A., & Yang, K. C. C. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00064-x · Cited by 35
Self-citationA Risk-Benefit Assessment of Pharmacological Treatments for Panic Disorder
Bennett, J. A., Moioffer, M., Stanton, S. P., Dwight, M. M., & Keck, P. E. (1998) · Drug Safety · doi:10.2165/00002018-199818060-00003 · Cited by 26
Research works printed but not linked: 4
- Woods, 1987, Pharmacol Rev, 39, 251
- Woods, 1992, Pharmacol Rev, 44, 151
- 1993, eports, 1, 19
- Uhlenhuth, 1995, Psychopharmacol Bull, 31, 289
Cited by
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049
Urine Drug Screening: Practical Guide for Clinicians
Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.1.66 · Cited by 543
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
Riemann, D., Baum, E., Cohrs, S., Crönlein, T., Hajak, G., Hertenstein, E., Klose, P., Langhorst, J., Mayer, G., Nissen, C., et al. (2017) · Somnologie · doi:10.1007/s11818-016-0097-x · Cited by 340
VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT
Vermeire, S., Audenaert, K., Vandermeulen, E., Mees, R. D., van Bree, H., Dobbeleir, A. A., Peremans, K. Y., De, R., Declercq, A., Maes, S., et al. (2011) · Cited by 297
Metadata
- Authors
- Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K.
- Affiliations
- University of New Mexico (US)
- Tufts University (US)
- Vanderbilt University (US)
- Corresponding author
- Uhlenhuth, E. H.
- ORCID
- Yang, Kenneth
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1999-12
- Volume
- 19
- Issue
- 6 Suppl 2
- Pages
- 23S-29S
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1979163345
- Cited by
- 80
- References
- 16
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2021: 1 · 2020: 23 · 2019: 6 · 2018: 1 · 2017: 5 · 2014: 2 · 2013: 1 · 2012: 3
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepines, anxiety disorders, abuse liability, long-term benzodiazepine use, withdrawal symptoms, benzodiazepine tapering, abrupt discontinuation, half-life, expert consensus, depressive disorders
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Depression, Humans, Surveys and Questionnaires, Substance Withdrawal Syndrome, Anti-Anxiety Agents, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. https://app.cochat.ai/papers/10.1097/00004714-199912002-00005
- The paper
- Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999). International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199912002-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.